PCN142 COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067
Abstract
Authors
T. Baker V.F. Paly H.M. Johnson H. Van Campenhout A. Amadi N. Chandran A. Moshyk S. Kotapati